Korean Circulation Journal

The Korean Society of Cardiology (대한심장학회)
권호 표지
DOI QR코드

DOI QR Code

Cardiovascular Safety of Celecoxib on Top of Dual Antiplatelet Therapy

  • Hong, Bum-Kee (Department of Cardiology, Gangnam Severance Hospital, Yonsei University College of Medicine)
  • Published : 2010.07.30
⟨ Previous Next ⟩

Abstract

Keywords

References

  1. Fitzgerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase- 2. N Engl J Med 2001;345:433-42. https://doi.org/10.1056/NEJM200108093450607
  2. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000;343:1520-8. https://doi.org/10.1056/NEJM200011233432103
  3. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: arandomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000; 284:1247-55. https://doi.org/10.1001/jama.284.10.1247
  4. Schnitzer TJ, Burmester GR, Mysler E, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 2004;364:665-74. https://doi.org/10.1016/S0140-6736(04)16893-1
  5. Abelson R, Gardiner H. Pfizer warns of risks from its painkiller. The New York Times 2004:B1.
  6. ADAPT Group. Cardiovasucalr and cerebrovascular events in the randomized controlled Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT). PLoS Clin Trials 2006;1:e33. https://doi.org/10.1371/journal.pctr.0010033
  7. Altman R, Luciardi HL, Muntaner J, et al. Efficacy assessment of meloxicam, a preferential cyclooxygenase-2 inhibitor, in acute coronary syndromes without ST-segment elevation: the Nonsteroidal Anti-Inflammatory Drugs in Unstable Angina Treatment-2 (NUT-2) pilot study. Circulation 2002;106:191-5. https://doi.org/10.1161/01.CIR.0000021599.56755.A1
  8. Chenevard R, Hurlimann D, Bechir M, et al. Selective COX-2 inhibition improves endothelial function in coronary artery disease. Circulation 2003;107:405-9. https://doi.org/10.1161/01.CIR.0000051361.69808.3A
  9. Whelton A, White WB, Bello AE, Puma JA, Fort JG. Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or =65 years of age with systemic hypertension and osteoarthritis. Am J Cardiol 2002;90:959-63. https://doi.org/10.1016/S0002-9149(02)02661-9
  10. Lee W, Suh JW, Yang HM, et al. Celecoxib does not attenuate the antiplatelet effects of aspirin and clopidogrel in healthy volunteers. Korean Circ J 2010;40:321-7. https://doi.org/10.4070/kcj.2010.40.7.321
  11. Wilner KD, Rushing M, Walden C, et al. Celecoxib does not affect the antiplatelet acitivey of aspirin in healthy volunteers. J Clin Pharmacol 2002;42:1027-30. https://doi.org/10.1177/0091270002042009010
  12. Renda G, Tacconelli S, Capone ML, et al. Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease. Clin Pharmacol Ther 2006;80-264-74. https://doi.org/10.1016/j.clpt.2006.05.004
  13. Kimmel SE, Berlin JA, Reilly M, et al. Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction. Ann Intern Med 2005;142:157-64. https://doi.org/10.7326/0003-4819-142-3-200502010-00005
  14. Burklow J, Ralbovsky D. NIH Halts Use of COX-2 Inhibitor in Large Cancer Prevention Trial. Bethesda, MD: U.S. Department of Health and Human Services, National Institutes of Health;2004.
  15. Yang HM, Kim HS, Park KW, et al. Celecoxib, a cyclooxygenase-2 inhibitor, reduces neointimal hyperplasia through inhibition of Akt signaling. Circulation 2004;110:301-8. https://doi.org/10.1161/01.CIR.0000135467.43430.16
  16. Wang K, Tarakji K, Zhou Z, et al. Celecoxib, a selective cyclooxygenase- 2 inhibitor, decreases monocyte chemoattractant protein-1 expression and neointimal hyperplasia in the rabbit atherosclerotic balloon injury model. J Cardiovasc Pharmacol 2005;45:61-7. https://doi.org/10.1097/00005344-200501000-00011